Revolution Medicines' targeted pill delivers striking survival advantage in pancreatic cancer
TL;DR Summary
In a trial for metastatic pancreatic cancer, Revolution Medicines' targeted pill daraxonrasib extended median overall survival to 13.2 months versus 6.7 months with chemotherapy, a dramatic near-doubling that experts described as very impressive.
Topics:business#biotech#daraxonrasib#overall-survival#pancreatic-cancer#revolution-medicines#targeted-therapy
- Revolution Medicines touts ‘unprecedented’ data for pancreatic cancer pill statnews.com
- Revolution Medicines' potential breakthrough pancreatic cancer drug succeeds in late-stage trial CNBC
- Daraxonrasib Demonstrates Unprecedented Overall Survival Benefit in Pivotal Phase 3 RASolute 302 Clinical Trial in Patients with Metastatic Pancreatic Cancer Yahoo Finance
- Revolution’s much-hyped RAS inhibitor hits key survival goals in phase 3 pancreatic cancer trial Fierce Biotech
- Revolution Medicines Stock Is Soaring 38%. Here’s Why. Barron's
Reading Insights
Total Reads
0
Unique Readers
24
Time Saved
2 min
vs 3 min read
Condensed
92%
405 → 33 words
Want the full story? Read the original article
Read on statnews.com